Stockscreener 앱 받기
295.59
1.25%
3.66
전일 마감가:
$291.93
열려 있는:
$291.8
하루 거래량:
266.70K
Relative Volume:
0.72
시가총액:
$32.40B
수익:
$3.81B
순이익/손실:
$-644.79M
주가수익비율:
-47.37
EPS:
-6.24
순현금흐름:
$-669.77M
1주 성능:
+9.60%
1개월 성능:
+19.63%
6개월 성능:
+33.02%
1년 성능:
+0.00%
1일 변동 폭
$289.11
$295.94
1주일 범위
$272.22
$300.00
52주 변동 폭
$172.67
$300.00
Beone Medicines Ltd Adr Stock (ONC) Company Profile
명칭
Beone Medicines Ltd Adr
전화
13459494123
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
모두보기
Beone Medicines Ltd Adr 주식(ONC)의 최신 뉴스
BeOne Medicines Ltd.Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? - MSN
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 1,363 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Down 3.6% After Insider Selling - Defense World
BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat
Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com
BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
LLY Stock Quote Price and Forecast - CNN
H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India
China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India
China approves novel HER2-targeted therapy for BTC - Investing.com Australia
BeiGene completes corporate re-domiciliation to Switzerland - Investing.com
BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com Nigeria
Daiwa Raises BEIGENE's TP to HKD180; Brukinsa Sales Growth Outpaces Competitors - AASTOCKS.com
BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India
Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com
Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX
BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com
BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins patent challenge against Pharmacyclics - Investing.com
BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions - Zacks Investment Research
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beone Medicines Ltd Adr (ONC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):